Blue Trust Inc. Boosts Stake in NeoGenomics, Inc. (NASDAQ:NEO)

Blue Trust Inc. boosted its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 42.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,318 shares of the medical research company’s stock after purchasing an additional 987 shares during the period. Blue Trust Inc.’s holdings in NeoGenomics were worth $46,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Susquehanna Fundamental Investments LLC acquired a new position in shares of NeoGenomics in the first quarter valued at approximately $680,000. Edgestream Partners L.P. acquired a new stake in NeoGenomics in the 1st quarter valued at about $1,894,000. Jennison Associates LLC grew its stake in NeoGenomics by 77.8% in the 1st quarter. Jennison Associates LLC now owns 1,051,627 shares of the medical research company’s stock valued at $16,532,000 after acquiring an additional 460,071 shares during the last quarter. Bellevue Group AG acquired a new stake in shares of NeoGenomics during the 1st quarter worth about $14,872,000. Finally, First Light Asset Management LLC boosted its stake in shares of NeoGenomics by 14.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock worth $52,464,000 after purchasing an additional 480,396 shares during the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics Price Performance

NASDAQ NEO opened at $14.00 on Friday. The stock’s 50-day moving average price is $14.80 and its two-hundred day moving average price is $14.70. The company has a current ratio of 2.01, a quick ratio of 1.93 and a debt-to-equity ratio of 0.37. The company has a market cap of $1.79 billion, a PE ratio of -22.58 and a beta of 1.19. NeoGenomics, Inc. has a 1 year low of $12.77 and a 1 year high of $21.22.

Wall Street Analysts Forecast Growth

NEO has been the topic of several research reports. Stephens restated an “overweight” rating and issued a $19.00 price target on shares of NeoGenomics in a report on Tuesday, July 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a report on Wednesday, September 25th. Finally, Benchmark reissued a “buy” rating and set a $18.00 price target on shares of NeoGenomics in a report on Tuesday, September 24th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, NeoGenomics presently has an average rating of “Moderate Buy” and a consensus target price of $19.89.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.